- 第III相ADMIRAL試験において治療抵抗性を示した患者に見られた新たな遺伝子変異について口頭発表予定 –

　アステラス製薬株式会社（本社：東京、代表取締役社長CEO：安川 健司、以下「アステラス製薬」）は、2019年12月7日から10日に米国フロリダ州オーランドで開催される第61回米国血液学会（American Society of Hematology: ASH）の年次総会において、急性骨髄性白血病（Acute Myeloid Leukemia; AML）に対するXOSPATA^®の新たなデータを発表します。

　以下の演題が口頭発表される予定です。

Title: Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 ADMIRAL Trial (Abstract 14)

Presenter: Catherine C. Smith, M.D., Division of Hematology and Blood and Marrow Transplantation, University of California San Francisco 

•     Session Date/Time: Saturday, Dec. 7, 7:45 a.m. EST
•     Location: Orange County Convention Center, W304 Level 3

　以下の演題がポスターまたはオンライン発表される予定です。

Title: The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3-Mutated (FLT3mut+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 ADMIRAL Study (Abstract 1332)

Lead Author: Ellen K. Ritchie, M.D., Weill Cornell Medicine, New York

•     Session Date/Time: Saturday, Dec. 7, 5:30-7:30 p.m. EST
•     Location: Orange County Convention Center, Hall B, Level 2

Title: The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 ADMIRAL Study (Abstract 3850)

Lead Author: David Cella, Ph.D., Northwestern University, Feinberg School of Medicine, Chicago

•     Session Date/Time: Monday, Dec. 9, 6-8 p.m. EST
•     Location: Orange County Convention Center, Hall B, Level 2

Title: Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) (Abstract 3859)

Lead Author: Amer M. Zeidan, MBBS, MHS, Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, Conn.

•     Session Date/Time: Monday, Dec. 9, 6-8 p.m. EST
•     Location: Orange County Convention Center, Hall B, Level 2 

Title: Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study (Abstract 3910) (Supported by AbbVie, Astellas and Genentech)

Lead Author: Alexander E. Perl, M.D., Abramson Cancer Center of the University of Pennsylvania, Philadelphia.

•     Session Date/Time: Monday, Dec. 9, 6-8 p.m. EST
•     Location: Orange County Convention Center, Hall B, Level 2 

Title: STREAMLINE - Study of Relapse or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study (Abstract 5082)

Lead Author: Amer M. Zeidan, MBBS, MHS, Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, Conn.

Title: Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive (FLT3mut+) Acute Myeloid Leukemia (AML) (Abstract 5085)

Lead Author: Amer M. Zeidan, MBBS, MHS, Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, Conn.

　アステラス製薬は、ASHの前日に開催されるFriday Satellite Symposia において、以下のシンポジウムを共催します。

Title: Data + Perspectives: Exploring the Role of Novel Agents and Emerging Strategies in the Management of Acute Myeloid Leukemia  

•     Session Date/Time: Friday, Dec. 6, 7-11 a.m. EST
•     Location: Hilton Orlando, Orange Ballroom 

Title: Treating Acute Myeloid Leukemia: Case Challenges and Emerging Therapies 

•     Session Date/Time: Friday, Dec. 6, 6-10 p.m. EST
•     Location: Hyatt Regency Orlando, Plaza International D-F 

以上